tiprankstipranks
Trending News
More News >
Cipla Ltd (IN:CIPLA)
:CIPLA
India Market
Advertisement

Cipla Ltd (CIPLA) AI Stock Analysis

Compare
7 Followers

Top Page

IN:CIPLA

Cipla Ltd

(CIPLA)

Select Model
Select Model
Select Model
Neutral 62 (OpenAI - 4o)
Rating:62Neutral
Price Target:
₹1,600.00
▲(7.04% Upside)
Cipla Ltd's overall stock score is primarily driven by its strong financial performance, which is offset by bearish technical indicators. The fair valuation suggests moderate growth potential, but the technical analysis indicates potential short-term challenges. The absence of earnings call data and corporate events means these factors do not influence the score.

Cipla Ltd (CIPLA) vs. iShares MSCI India ETF (INDA)

Cipla Ltd Business Overview & Revenue Model

Company DescriptionCipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.
How the Company Makes MoneyCipla makes money through the sale of pharmaceutical products across various therapeutic segments. Its revenue model is primarily based on generic drug manufacturing, where it develops cost-effective versions of branded drugs once their patents expire. Key revenue streams include domestic sales in India, which contribute significantly to its earnings, and international markets, notably in North America, Europe, and emerging markets. Cipla's earnings are also bolstered by its strategic partnerships and collaborations with other pharmaceutical companies to co-develop and supply medications globally. The company invests in research and development to expand its product portfolio and enhance its presence in specialty therapeutics, thereby driving growth and profitability.

Cipla Ltd Financial Statement Overview

Summary
Cipla Ltd demonstrates strong financial performance with impressive revenue and profit growth, efficient cost management, and robust operational margins. The low debt-to-equity ratio and high equity ratio underscore financial stability, while strong cash flow metrics highlight effective cash management.
Income Statement
85
Very Positive
Cipla Ltd has shown a strong revenue growth trajectory, with a 6.68% increase in total revenue from 2024 to 2025. The gross profit margin remains robust at approximately 67.13% for 2025, indicating efficient cost management. The net profit margin improved to 19.42%, reflecting enhanced profitability. EBIT and EBITDA margins are also strong at 49.29% and 26.25%, respectively, showcasing solid operational performance.
Balance Sheet
80
Positive
The company exhibits a healthy balance sheet with a low debt-to-equity ratio of 0.01, suggesting low leverage and financial stability. Return on equity is impressive at 16.90%, indicating effective use of equity capital. The equity ratio of 83.41% demonstrates a strong equity base relative to total assets, highlighting financial resilience.
Cash Flow
78
Positive
Cipla's cash flow metrics are positive, with a notable free cash flow growth rate of 37.97% from 2024 to 2025. The operating cash flow to net income ratio is 0.95, indicating a good conversion of profits into cash. The free cash flow to net income ratio stands at 0.73, reflecting sound cash generation relative to earnings.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue276.00B272.67B255.37B225.59B217.08B191.21B
Gross Profit168.82B180.92B164.93B141.04B130.18B116.14B
EBITDA73.89B70.22B61.91B49.19B44.39B41.24B
Net Income53.92B52.73B41.22B28.02B25.17B24.05B
Balance Sheet
Total Assets0.00373.87B327.18B294.63B271.01B251.52B
Cash, Cash Equivalents and Short-Term Investments106.17B106.17B77.96B62.77B46.32B37.46B
Total Debt0.004.39B5.60B8.03B10.56B20.24B
Total Liabilities-312.89B60.98B59.15B57.50B59.84B65.66B
Stockholders Equity312.89B311.93B267.07B234.08B208.42B183.27B
Cash Flow
Free Cash Flow0.0038.43B27.85B20.55B26.25B29.36B
Operating Cash Flow0.0050.05B41.34B32.38B33.26B37.55B
Investing Cash Flow0.00-36.91B-29.88B-23.89B-18.72B-23.87B
Financing Cash Flow0.00-12.93B-12.00B-9.58B-16.00B-12.40B

Cipla Ltd Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1494.70
Price Trends
50DMA
1543.18
Negative
100DMA
1513.84
Negative
200DMA
1487.05
Positive
Market Momentum
MACD
-12.63
Positive
RSI
44.71
Neutral
STOCH
49.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CIPLA, the sentiment is Neutral. The current price of 1494.7 is below the 20-day moving average (MA) of 1531.23, below the 50-day MA of 1543.18, and above the 200-day MA of 1487.05, indicating a neutral trend. The MACD of -12.63 indicates Positive momentum. The RSI at 44.71 is Neutral, neither overbought nor oversold. The STOCH value of 49.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:CIPLA.

Cipla Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
₹319.56B41.490.93%-2.34%6.64%
69
Neutral
₹237.23B29.340.67%4.35%32.89%
66
Neutral
₹463.99B48.831.96%6.65%48.47%
62
Neutral
₹1.21T22.390.86%6.40%25.27%
62
Neutral
₹634.29B43.671.60%11.17%17.22%
62
Neutral
₹109.17B30.122.49%-23.93%-31.53%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:CIPLA
Cipla Ltd
1,512.55
-88.88
-5.55%
IN:ABBOTINDIA
Abbott India Limited
29,679.25
1,693.94
6.05%
IN:GLAND
Gland Pharma Ltd.
1,955.05
270.19
16.04%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,758.60
46.87
1.73%
IN:PFIZER
PFIZER LIMITED
5,263.35
-319.50
-5.72%
IN:SANOFI
Sanofi India Limited
4,709.10
-2,064.64
-30.48%

Cipla Ltd Corporate Events

Cipla Ltd Allots 2,853 Equity Shares Under Employee Stock Schemes
Aug 2, 2025

Cipla Limited has announced the allotment of 2,853 equity shares under its Employee Stock Option Scheme 2013-A and the Cipla Employee Stock Appreciation Rights Scheme 2021. This move increases the company’s issued, subscribed, and paid-up share capital to INR 1,61,55,08,148, reflecting its ongoing commitment to employee engagement and retention strategies.

Cipla Opens Special Window for Physical Share Transfers
Aug 2, 2025

Cipla Ltd announced the opening of a special window for the re-lodgement of transfer requests for physical shares, as per the SEBI regulations. This initiative, communicated through newspaper advertisements, aims to facilitate shareholders in transferring their physical shares, reflecting the company’s commitment to compliance and shareholder engagement.

Cipla Ltd Announces Strong Q1 2025 Financial Results
Jul 27, 2025

Cipla Ltd has released its unaudited financial results for the quarter ended June 30, 2025, showing a revenue from continuing operations of ₹3,719 crore and a net profit of ₹316 crore. The results indicate a significant improvement in profitability compared to the previous quarter, reflecting Cipla’s robust operational performance and strategic market positioning. This financial update is crucial for stakeholders as it highlights the company’s resilience and growth potential in the competitive pharmaceutical industry.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 26, 2025